Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

Kavanagh, D. ; Gerogianni, A. LU ; Karpman, D. LU orcid and Greenbaum, Larry A. (2024) In Kidney International 106(6). p.1038-1050
Abstract
Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement... (More)
Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described. © 2024 International Society of Nephrology (Less)
Please use this url to cite or link to this publication:
author
; ; and
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
acute kidney injury, C5, complement, hemolytic uremic syndrome, thrombotic microangiopathy, Atypical Hemolytic Uremic Syndrome, Biomarkers, Complement Inactivating Agents, Complement System Proteins, Hemolytic-Uremic Syndrome, Humans, Kidney Transplantation, Nephrology, Societies, Medical, cobalamin, complement component C3, complement component C3b, complement component C3d, eculizumab, homocysteine, immunoglobulin G, interleukin 18, interleukin 2, properdin, ravulizumab, thrombomodulin, biological marker, complement inhibitor, activated partial thromboplastin time, anticoagulation, antiphospholipid syndrome, Article, chronic kidney failure, complement activation, complement inhibition, computer assisted tomography, creatinine blood level, disease activity, disseminated intravascular clotting, estimated glomerular filtration rate, exosome, female, focal glomerulosclerosis, gene mutation, genetic screening, genotype, glomerulopathy, glomerulus filtration rate, haplotype, hematuria, human, hypertension, immunoglobulin A nephropathy, immunosuppressive treatment, kidney biopsy, kidney function, kidney transplantation, liver function test, membranoproliferative glomerulonephritis, membranous glomerulonephritis, meningococcosis, metabolic syndrome X, methylmalonic aciduria, microangiopathy, mouse, nephrotic syndrome, nonhuman, nuclear magnetic resonance imaging, plasma exchange, plasmapheresis, polymerase chain reaction, prevalence, prospective study, prothrombin time, renal replacement therapy, retrospective study, seasonal variation, thrombocytopenia, thrombotic thrombocytopenic purpura, vaccination, virus replication, adverse event, atypical hemolytic uraemic syndrome, blood, diagnosis, drug therapy, genetics, immunology, medical society, nephrology, procedures, therapy
in
Kidney International
volume
106
issue
6
pages
13 pages
publisher
Nature Publishing Group
external identifiers
  • scopus:85209153266
  • pmid:39395628
ISSN
0085-2538
DOI
10.1016/j.kint.2024.09.012
language
English
LU publication?
yes
additional info
Number of authors = 83 EID = 85209153266 Start page = 1038 End page = 1050 Affiliation = Kavanagh D., National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom, Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom Affiliation = Zhang Y., University of Iowa, Iowa City Affiliation = Prohászka Z., Semmelweis University, Budapest
id
3074a556-74c1-4eaf-83b5-af09038ee5c8
date added to LUP
2025-10-07 12:42:38
date last changed
2025-10-14 12:11:45
@article{3074a556-74c1-4eaf-83b5-af09038ee5c8,
  abstract     = {{Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described. © 2024 International Society of Nephrology}},
  author       = {{Kavanagh, D. and Gerogianni, A. and Karpman, D. and Greenbaum, Larry A.}},
  issn         = {{0085-2538}},
  keywords     = {{acute kidney injury; C5; complement; hemolytic uremic syndrome; thrombotic microangiopathy; Atypical Hemolytic Uremic Syndrome; Biomarkers; Complement Inactivating Agents; Complement System Proteins; Hemolytic-Uremic Syndrome; Humans; Kidney Transplantation; Nephrology; Societies, Medical; cobalamin; complement component C3; complement component C3b; complement component C3d; eculizumab; homocysteine; immunoglobulin G; interleukin 18; interleukin 2; properdin; ravulizumab; thrombomodulin; biological marker; complement inhibitor; activated partial thromboplastin time; anticoagulation; antiphospholipid syndrome; Article; chronic kidney failure; complement activation; complement inhibition; computer assisted tomography; creatinine blood level; disease activity; disseminated intravascular clotting; estimated glomerular filtration rate; exosome; female; focal glomerulosclerosis; gene mutation; genetic screening; genotype; glomerulopathy; glomerulus filtration rate; haplotype; hematuria; human; hypertension; immunoglobulin A nephropathy; immunosuppressive treatment; kidney biopsy; kidney function; kidney transplantation; liver function test; membranoproliferative glomerulonephritis; membranous glomerulonephritis; meningococcosis; metabolic syndrome X; methylmalonic aciduria; microangiopathy; mouse; nephrotic syndrome; nonhuman; nuclear magnetic resonance imaging; plasma exchange; plasmapheresis; polymerase chain reaction; prevalence; prospective study; prothrombin time; renal replacement therapy; retrospective study; seasonal variation; thrombocytopenia; thrombotic thrombocytopenic purpura; vaccination; virus replication; adverse event; atypical hemolytic uraemic syndrome; blood; diagnosis; drug therapy; genetics; immunology; medical society; nephrology; procedures; therapy}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{1038--1050}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Kidney International}},
  title        = {{Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum}},
  url          = {{http://dx.doi.org/10.1016/j.kint.2024.09.012}},
  doi          = {{10.1016/j.kint.2024.09.012}},
  volume       = {{106}},
  year         = {{2024}},
}